New tools and approaches for improved management of inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 8, Issue 10, 2014, Pages 1246-1253

  Ghosh, Subrata ^a   Pariente, Benjamin ^b   Mould, Diane R ^c   Schreiber, Stefan ^d   Petersson, Joel ^e   Hommes, Daniel ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b SAINT LOUIS HOSPITAL   (France)

^c Projections Research Inc   (United States)

^d UNIVERSITY OF KIEL   (Germany)

^e ABBVIE INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Disease monitoring; Healthcare delivery; Individualised medicine; Ulcerative colitis; Value

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; CROHN DISEASE; HEALTH CARE QUALITY; HEALTH DISPARITY; HUMAN; INFLAMMATORY BOWEL DISEASE; MEDICAL CARE; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PATIENT CARE; PUBLIC-PRIVATE PARTNERSHIP; SCORING SYSTEM; STANDARD; COLITIS, ULCERATIVE; INTERDISCIPLINARY COMMUNICATION; PATHOLOGY; PERSONALIZED MEDICINE; TOTAL QUALITY MANAGEMENT;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; INTERDISCIPLINARY COMMUNICATION; QUALITY IMPROVEMENT;

EID: 84908231842     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.02.026     Document Type: Article

References (44)

1. Cassinotti A., Keshav S., Ardizzone S., Mortensen N., Sampietro G., Fociani P., et al. IBD care in Europe: a comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the national UK IBD audit tool. J Crohns Colitis 2009, 3:291-301.
2. Colletti R.B., Baldassano R.N., Milov D.E., Margolis P.A., Bousvaros A., Crandall W.V., et al. Network for research improvement. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2009, 49:297-303.
3. Benchimol E.I., Cook S.F., Erichsen R., Long M.D., Bernstein C.N., Wong J., et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis 2013, 7:878-889.
4. Ghosh S., Schreiber S., Petkau J., Bressler B., Thakkar R.B., Yang M., et al. Evaluating clinical practice patterns with inflammatory bowel disease health care assessment questionnaires (POLARIS): a patient- and a physician-reported survey. J Crohns Colitis 2013, 7(Suppl. 1):S124. [Abstract 509].
5. American Gastroenterological Association Adult inflammatory bowel disease physician performance measures set: American gastroenterological association 2011, [Available at: www.ama-assn.org/resources/doc/pcpi/inflammatory-bowel-disease.pdf].
6. IBD Standards Group Quality care service standards for the healthcare of people who have inflammatory bowel disease (IBD) 2009, St Albans: Oyster Healthcare Communications Ltd., [Available at: www.bsg.org.uk/attachments/160_IBDstandards.pdf].
7. Melmed G.Y., Siegel C.A., Spiegel B.M., Allen J.I., Cima R., Colombel J.F., et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis 2013, 19:662-668.
8. Rocchi A., Benchimol E.I., Bernstein C.N., Bitton A., Feagan B., Panaccione R., et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol 2012, 26:811-817.
9. Gunnarsson C., Chen J., Rizzo J.A., Ladapo J.A., Lofland J.H. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci 2012, 57:3080-3091.
10. Buchanan J., Wordsworth S., Ahmad T., Perrin A., Vermeire S., Sans M., et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis 2011, 5:301-316.
11. Park K.T., Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis 2011, 17:1603-1609.
12. Cohen R.D., Waters H.C., Tang B., Rahman M.I. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis 2008, 14:1707-1714.
13. Hillson E., Dybicz S., Waters H.C., Stuart B., Schaneman J., Dabbous O., et al. Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. J Occup Environ Med 2008, 50:969-977.
14. Kane S., Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008, 53:1020-1024.
15. Porter M.E. A strategy for health care reform-toward a value-based system. N Engl J Med 2009, 361:109-112.
16. Porter M.E. What is value in health care?. N Engl J Med 2010, 363:2477-2481.
17. Thia K.T., Sandborn W.J., Harmsen W.S., Zinsmeister A.R., Loftus E.V. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:1147-1155.
18. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
19. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
20. Guyatt G., Mitchell A., Irvine E.J., Singer J., Williams N., Goodacre R., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
21. Irvine E.J. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999, 28:S23-S27.
22. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
23. Daperno M., D'Haens G., Van Assche G., Baert F., Bulois P., Maunoury V., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
24. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
25. D'Haens G.R., Geboes K., Peeters M., Baert F., Penninckx F., Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262-267.
26. Pariente B., Cosnes J., Danese S., Sandborn W.J., Lewin M., Fletcher J.G., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011, 17:1415-1422.
27. Pariente B., Mary J-Y., Colombel J-F., Cosnes J. The International Program to develop New Indexes in Crohn's disease (IPNIC) group. Development of the Crohn's disease (CD) digestive damage score: the Lémann score. J Crohns Colitis 2013, 7(Suppl. 1):S3. [Abstract 6].
28. Torres J., Billioud V., Sachar D.B., Peyrin-Biroulet L., Colombel J.F. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012, 18:1356-1363.
29. Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
30. Ordas I., Feagan B.G., Sandborn W.J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:1079-1087.
31. Ordas I., Mould D.R., Feagan B.G., Sandborn W.J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012, 91:635-646.
32. Colombel J.F., Feagan B.G., Sandborn W.J., Van Assche G., Robinson A.M. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:349-358.
33. Seow C.H., Newman A., Irwin S.P., Steinhart A.H., Silverberg M.S., Greenberg G.R. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
34. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
35. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
36. Fasanmade A.A., Adedokun O.J., Ford J., Hernandez D., Johanns J., Hu C., et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009, 65:1211-1228.
37. Bendtzen K., Ainsworth M., Steenholdt C., Thomsen O.O., Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 44:774-781.
38. Fasanmade A.A., Adedokun O.J., Blank M., Zhou H., Davis H.M. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011, 33:946-964.
39. Fasanmade A.A., Adedokun O.J., Olson A., Strauss R., Davis H.M. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010, 48:297-308.
40. Vande Casteele N., Gils A., Ballet V., Compernolle G., Peeters M., Van Steen K., et al. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT study. United European Gastroenterology Week 2013, [Abstract OP001].
41. Vande Casteele N., Compernolle G., Ballet V., Van Assche G., Vermiere S., Rutgeerts P. Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial 2012, Congress of the European Crohn's and Colitis Organisation, [Abstract OP11].
42. Vavricka S.R., Brun L., Ballabeni P., Pittet V., Prinz Vavricka B.M., Zeitz J., et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011, 106:110-119.
43. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009, 10:43-55.
44. Barrenas F., Chavali S., Alves A.C., Coin L., Jarvelin M.R., Jornsten R., et al. Highly interconnected genes in disease-specific networks are enriched for disease-associated polymorphisms. Genome Biol 2012, 13:R46.